Company intelligence / Profile preview

NeOnc Technologies Holdings, Inc.

Westlake Village / Calabasas*, California, United Statesneonctech.com ↗

Ownership: Public · NTHI
Employees: ~8
Development stage: Other

Overview

NeOnc’s lead candidate NEO100 is in a Phase 2a trial for malignant gliomas with IDH1 mutations. Early data from a completed Phase 1 study showed the intranasal therapy was safe and well tolerated; some patients experienced extended survival compared to historical controls. The company expects full enrollment of its current trial by September 2025 with read-out data anticipated in early 2026.

Therapeutic areas: Oncology
Modalities: Small molecules (notably perillyl alcohol derivatives)
Industry: Biotech

Drug pipeline

4 assets

NEO-212

3 more assets in the full pipeline.

Partnerships

University of Southern California (exclusive worldwide patent license)

Financials

Market cap: $92.2M
Total revenue: $40K
Enterprise value: $86.3M

Beyond the preview

Go deeper on NeOnc Technologies Holdings, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeOnc Technologies Holdings, Inc..